ConferencePoster
 (2024)

Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005

Seo, S; Calderon, B; Chou, HH; Hsu, CH; Salman, P; Ghiringhelli, F; Ozyilkan, O; Rojas, CI; Sendur, M.A.N; Le Tourneau, C